The aim of the study was to determine if the use of escalating doses of interferon and ribavirin along with growth factors increases adherence to therapy in patients with recurrent hepatitis C (HCV). Ten patients with HCV genotype 1 following liver transplant were enrolled. Post-treatment liver biopsies showed stable or improved disease in six out of nine patients. Our findings suggest that in patients with recurrent HCV after liver transplantation, starting low doses of interferon and ribavirin along with use of growth factors allows for ≥80% drug dose adherence. By using pegylated interferons, or possibly the new polymerase or protease inhibitors, we can expect better results. Transplant patients with recurrent HCV remain a clinical challenge with suboptimal response and tolerance to current antiviral therapy.
|Original language||English (US)|
|Number of pages||10|
|State||Published - May 2007|
ASJC Scopus subject areas